Realistic illustration of a doctor reviewing mailed abortion pills received despite health risks in a test order for a young patient.
Realistic illustration of a doctor reviewing mailed abortion pills received despite health risks in a test order for a young patient.
AI:n luoma kuva

Anti-abortion OB-GYN group says Aid Access mailed abortion pills after test order flagged health risks

AI:n luoma kuva
Faktatarkistettu

The American Association of Pro-Life Obstetricians & Gynecologists (AAPLOG) says it submitted a test order to Aid Access posing as a 13-year-old with multiple medical risk factors and received abortion medication by mail, raising questions about screening practices for online medication-abortion services.

The American Association of Pro-Life Obstetricians & Gynecologists (AAPLOG), an advocacy group that opposes abortion, says its CEO, Dr. Christina Francis, submitted an online request for abortion pills to Aid Access using information indicating the patient was 13 years old and had multiple potential medical red flags.

According to accounts published by The Daily Wire and other conservative outlets, the submission listed conditions and circumstances that could require careful clinical assessment—such as use of blood thinners, having an intrauterine device (IUD), a prior ectopic pregnancy and multiple prior cesarean sections—and the service nevertheless proceeded to payment and shipment. Those reports also say the package arrived in Indiana within days and listed a California return address.

AAPLOG has argued that the episode shows insufficient identity verification and inadequate medical screening for online abortion-pill requests. Aid Access did not respond to comment requests in the reporting reviewed.

The group has urged federal lawmakers to revisit the U.S. Food and Drug Administration’s rules for mifepristone distribution, including reinstating an in-person dispensing requirement. The FDA, however, has said the current mifepristone Risk Evaluation and Mitigation Strategy (REMS) does not require an in-person visit before a patient obtains the drug and that the agency approved changes that removed the in-person dispensing requirement while maintaining other REMS safeguards, such as prescriber certification and a patient agreement form.

The episode described by AAPLOG has not been independently verified in widely sourced, mainstream reporting, and the details available publicly largely come from advocacy-aligned or partisan outlets.

Mitä ihmiset sanovat

Initial reactions on X highlight concerns over Aid Access's screening practices following AAPLOG's undercover test order, with pro-life advocates praising the exposure of potential medical risks.

Liittyvät artikkelit

Dramatic courtroom scene of Fifth Circuit judges issuing nationwide block on telehealth mifepristone prescribing and mailing.
AI:n luoma kuva

Fifth Circuit temporarily blocks telehealth prescribing and mailing of mifepristone nationwide

Raportoinut AI AI:n luoma kuva Faktatarkistettu

A unanimous three-judge panel of the U.S. Court of Appeals for the Fifth Circuit on Friday issued a temporary nationwide order that freezes federal rules allowing mifepristone to be prescribed via telemedicine and sent by mail, siding with Louisiana in a lawsuit challenging the FDA’s 2023 changes.

The U.S. Supreme Court on Thursday issued an emergency order permitting the mail distribution of the abortion drug mifepristone to continue nationwide. The unsigned ruling temporarily blocked a federal appeals court decision that had struck down a Biden-era policy allowing online prescriptions and shipments.

Raportoinut AI

The Supreme Court is addressing challenges to medication abortion rules.

More than 50 Republican lawmakers have urged acting Attorney General Todd Blanche to investigate the circumstances surrounding the recovery of five sets of fetal remains in Washington, D.C., in 2022, including whether any federal crimes were committed, according to a letter publicized by Rep. Chris Smith’s office and reported by The Daily Wire.

Tämä verkkosivusto käyttää evästeitä

Käytämme evästeitä analyysiä varten parantaaksemme sivustoamme. Lue tietosuojakäytäntömme tietosuojakäytäntö lisätietoja varten.
Hylkää